Longer‐Period Effects of Bicarbonate/Lactate‐Buffered Neutral Peritoneal Dialysis Fluid in Patients Undergoing Peritoneal Dialysis. Issue 6 (16th July 2018)

• Record Type: Journal Article
• Authors: Hoshino, Taro; Kaneko, Shohei; Minato, Saori; Yanai, Katsunori; Mutsuyoshi, Yuko; Ishii, Hiroki; Kitano, Taisuke; Shindo, Mitsutoshi; Miyazawa, Haruhisa; Aomatsu, Akinori; Ito, Kiyonori; Ueda, Yuichiro; Hirai, Keiji; Ookawara, Susumu; Morishita, Yoshiyuki
• Is Part Of: Therapeutic apheresis and dialysis. Volume 22:Issue 6(2018)
• Page Start: 641
• Page End: 648
• Publication Date: 2018-07-16
• Subjects: Bicarbonate -- Lactate -- Peritoneal dialysis -- Peritoneal dialysis fluid -- Peritoneal membrane preservation; Hemapheresis -- Periodicals; Dialysis -- Periodicals; Blood Component Removal -- Periodicals; Renal Dialysis -- Periodicals; Hémaphérèse -- Périodiques; Dialyse -- Périodiques; Sang -- Collecte et conservation -- Périodiques; 616
• DOI: 10.1111/1744-9987.12709
• Languages: English
• ISSNs: 1744-9979

Abstract

Abstract: High concentrations of lactate are considered to contribute to impairment of the peritoneal membrane. We investigated the longer‐period effects of bicarbonate/lactate‐buffered neutral peritoneal dialysis fluid (PDF) in patients undergoing PD for about 2 years. Patients undergoing PD were changed from a lactate‐buffered neutral PDF to a bicarbonate/lactate‐buffered neutral PDF. We then investigated the patients' clinical outcomes and peritoneal membrane functions as well as the surrogate markers in the drained dialysate. Fourteen patients undergoing PD were enrolled. Peritonitis was observed in one patient. No other adverse events were observed. Peritoneal function did not change as the ultrafiltration volume decreased. Fibrin degradation products and vascular endothelial growth factor in the drained dialysate decreased while the interleukin level increased. These results suggest that bicarbonate/lactate‐buffered neutral PDF may have beneficial effects in terms of peritoneal preservation and can be safely used in patients undergoing PD.